Does Nebraska Medicaid Cover Wegovy or Zepbound? Heritage Health GLP-1 Rules

No. As of November 2026, Nebraska Medicaid, including its Heritage Health plans, does not pay for Wegovy, Zepbound or any drug prescribed for weight control.^[1] Its prior authorization forms do cover Wegovy to cut heart risk in adults aged 45 to 74 or to treat the liver disease MASH, and Zepbound for moderate to severe sleep apnea, each only after six months in a medically supervised weight program.^[2][3]

Will Nebraska Medicaid pay for Wegovy or Zepbound to lose weight?

It will not. Nebraska’s pharmacy rules list drugs “prescribed or recommended for weight control or appetite suppression” among the items Medicaid will not pay for.^[1] The state forms repeat the point in their own way: the Zepbound form says the drug is covered only for sleep apnea, and the Wegovy form names heart risk and MASH as its two covered uses.^[2][3] Neither drug appears on the November 2026 preferred drug list.^[4]

Under federal law, states may exclude weight-loss drugs from Medicaid, and Nebraska is one of many that do.^[10] Our explainer on why Medicaid pays for Ozempic but not Wegovy covers the federal background.

Do Heritage Health plans follow the same rules?

As far as we could read, yes. Heritage Health, the state’s Medicaid managed care program, runs through three plans: Nebraska Total Care, Molina and UnitedHealthcare Community Plan.^[6] Nebraska Total Care’s Wegovy policy for its Medicaid members uses the state’s criteria nearly word for word, including the age range, the A1C limit and the six-month program.^[5][2] We did not find published Wegovy or Zepbound criteria for the other two plans, so members of those plans should ask the plan for its form. The state forms in this article are written for fee-for-service members and send requests to Prime Therapeutics, the state’s pharmacy contractor.^[2]

Which GLP-1 uses does Nebraska Medicaid cover?

The six-month program is the step people most often lack. For each route, the form asks whether the patient has finished at least six months of weight management supervised by a physician, nurse practitioner or physician assistant, covering behavior change, a reduced-calorie diet and more activity.^[2][3] A note in the chart that the patient was told to diet will not meet that. A documented, dated program will.

Who qualifies for Wegovy for heart disease in Nebraska?

An adult between 45 and 74 with a documented heart attack or stroke, or with artery disease in the legs that causes symptoms, shown by leg pain on walking with an ankle-brachial index under 0.85, a past artery procedure or an amputation from artery disease.^[2] The person must not have diabetes and must have an A1C below 6.5%, and the BMI must reach 30, or 27 when a weight-related condition is also present.^[2] The form also asks the prescriber to confirm the patient takes the heart medicines already prescribed.^[2]

The age window is stricter than the label, which sets no upper age for adults who have heart disease along with excess weight.^[12] Someone who is 76 with a past heart attack meets the label but not Nebraska’s form. Renewal comes after six months and lasts 12; it needs a stable maintenance dose and a loss of 5% or more of starting weight, either newly reached or held since the first approval.^[2]

What does Nebraska ask for with Wegovy and MASH?

Proof of the scarring stage, and recent proof. The fibrosis must be stage F2 or F3, confirmed by a FibroScan, magnetic resonance elastography or ELF blood test from the past six months, or a liver biopsy from the past 12 months.^[2] An endocrinologist, gastroenterologist or liver specialist must prescribe it or be consulted, and Wegovy cannot be combined with Rezdiffra, the other MASH drug.^[2]

This is the one route open to people with type 2 diabetes, provided Ozempic has been tried first; Nevada Medicaid’s MASH route sets no diabetes bar at all.^[2] Nebraska Total Care sets the same condition and asks to see it in paid pharmacy claims.^[5] Renewal needs fibrosis that has improved or held steady and no cirrhosis.^[2] Our page on semaglutide for MASH covers the trial behind the label, which the FDA approved on an accelerated basis.^[12]

What does Nebraska require for Zepbound and sleep apnea?

A long list. Beyond an AHI of at least 15 on a sleep study (or the same score on the related RDI or REI scales), a BMI of 30 or more and no diabetes, the patient must have tried both breathing-device therapy and an oral appliance, and each must have failed, been poorly tolerated, or been unsuitable.^[3] The six-month weight program here also includes advice to avoid sleeping on the back and to avoid alcohol and sedatives at bedtime.^[3] A sleep specialist must prescribe it or be consulted.^[3]

The patient must keep using PAP, which the form defines as at least four hours a night on at least 70% of nights for two months or more.^[3] Central or mixed sleep apnea, major craniofacial abnormalities, or planned surgery for sleep apnea or obesity rule the request out.^[3] Renewals run six months until the patient reaches 52 weeks on a maintenance dose of 10 or 15 mg, then 12 months, and each needs a lower apnea score than at baseline.^[3] The label itself requires none of the device steps.^[11] Our guide to how Zepbound was tested for sleep apnea explains the trials.

Does Nebraska Medicaid cover Ozempic for diabetes?

Yes. Ozempic, Trulicity and Victoza are the preferred GLP-1s. They need a type 2 diabetes diagnosis and a failed or poorly tolerated trial of metformin, though people with diabetes and heart or artery disease can skip the metformin step.^[4] Mounjaro and the Ozempic tablet are non-preferred: they need failures on two preferred GLP-1s, an A1C of 7 or higher and a metformin trial.^[4] Rybelsus, listed as non-preferred in October, is not on the November 2026 list.^[4]

How do you file, and how do you appeal a denial?

Fee-for-service prescribers fax the drug’s form, with the supporting records, to Prime Therapeutics at 866-759-4115; the help line is 800-241-8335.^[2][3] Heritage Health members’ prescribers file with the member’s plan.

Appeals depend on the plan type. A Heritage Health member first appeals to the plan, and federal rules give 60 days from the date on the denial notice to do so.^[7] When the plan’s answer is still no, the member then has at least 90 and at most 120 days from the plan’s decision to ask the state for a fair hearing.^[8] For fee-for-service members, federal rules cap the state’s deadline at 90 days from the date the notice is mailed.^[9] The exact deadline is printed on the notice, so use that date. Our guide to preparing a GLP-1 prior authorization appeal covers what to include, and the Nebraska state page collects the main facts.

What can you do if Nebraska Medicaid denies coverage?

Paying out of pocket is the main fallback, because manufacturer copay cards exclude Medicaid members.^[13] As of November 2026, Novo Nordisk’s self-pay price is $349 a month for most Wegovy pen doses, and the Wegovy pill starts at $149.^[14] Lilly sells Zepbound for $299 at the starting dose and $399 at 5 mg, with $449 for higher doses when refills stay on schedule.^[13] Read each offer’s terms on government insurance first. Our guide to the least expensive GLP-1 options without coverage compares them.